Correlation between the Distribution of Traditional Chinese Medicine Syndromes and Molecular Types of Breast Cancer in Perichemotherapy Period

Abstract

Objectives The objective of this study was to explore the correlation between the distribution of traditional Chinese medicine (TCM) syndromes and molecular types of breast cancer in the perichemotherapy period.

Methods A total of 325 cases with perichemotherapy breast cancer was classified according to syndrome differentiation in TCM , and R × C table χ² test was used to examine and analyze the relationship between TCM syndromes and molecular types of breast cancer in the perichemotherapy period.

Results (1) In the early stage of chemotherapy, there was no significant difference in the distribution of different TCM syndromes among molecular types, mainly liver depression syndrome and liver depression and phlegm coagulation syndrome (p > 0.05). (2) In the middle stage of chemotherapy, there were significant differences in the distribution of spleen deficiency and phlegm-dampness syndrome among HER-2 positive (HR positive), HER-2 positive (HR negative), and Luminal A type, Luminal B type (HER-2 negative), and triple-negative type (p < 0.01). (3) After chemotherapy, there were significant differences in the distribution of spleen and kidney yang deficiency syndrome and marrow sea insufficiency syndrome among HER-2 positive (HR negative), triple-negative type, and HER-2 positive (HR positive), Luminal A type, Luminal B type (HER-2 negative), and triple-negative type (p < 0.01).

Conclusion (1) In the middle stage of chemotherapy, HER-2 positive (HR positive) and HER-2 positive (HR negative) are more likely to show spleen deficiency and phlegm-dampness syndrome than other molecular types. (2) In the late stage of chemotherapy, the HER-2 positive (HR negative) and triple-negative type is more likely to show spleen-kidney yang deficiency syndrome than other molecular types, and the triple-negative type is more likely to show marrow sea insufficiency syndrome than other molecular types.

Keywords

breast cancer - perichemotherapy - TCM syndromes - molecular types

Authors' Contribution

B.M. was responsible for conceptualization, data curation, formal analysis, investigation, and writing—original draft. X.C. was responsible for writing—original draft, data curation, funding acquisition, project administration, supervision, and writing—review and editing. Q.L. was responsible for data curation, formal analysis, investigation, and writing—review and editing. H.Z. was responsible for data curation, formal analysis, and investigation. B.W. was responsible for data curation, formal analysis, investigation, data curation, investigation, and writing—original draft. L.X. was responsible for data curation, formal analysis, investigation, and writing—original draft.

Publikationsverlauf

Eingereicht: 10. Juli 2023

Angenommen: 25. August 2023

Artikel online veröffentlicht:
28. Dezember 2023

• References

• 1 Oncology Medicine Forum. Interpretation of the latest global cancer data in 2020. Chin J Clin Oncol Rehabil 2021; 28 (03) 301
• 2 Lyu F, Zhu GG, Liu T. et al. Clinical study on Xinmailong injection in the treatment of chronic congestive heart failure. Chin J Integr Med Cardio/Cerebrovascular Dis 2015; 13 (01) 83-84
• 3 Yang ZH, Que YM, Zhou XF. et al. Discussion on the efficacy and side effects of Shenqi Fuzheng injection combined with chemotherapy in the treatment of advanced gastric cancer. Zhonghua Zhongyiyao Xuekan 2015; 33 (03) 732-734
• 4 Huang XP, Li F, Chen LB. et al. Effects of Astragalus-Angelica compatilibity on bone marrow hematopoiesis suppression induced by Cyclophosphamide in mice. Chin Tradit Herbal Drugs 2017; 48 (01) 121-128
• 5 Liu Y, Li XM. Progress of the prevention and treatment of hand-foot syndrome induced by chemotherapeutic drugs with integrated Chinese and Western medicine. Electron J Clin Med Lit 2020; 7 (52) 189-190
• 6 Gong LY, Chen HF. Correlation study between syndrome types of Chinese medicine and molecular types of breast cancer in consolidate period. Chung Kuo Chung Hsi I Chieh Ho Tsa Chih 2017; 37 (02) 174-178
• 7 Specialty Committee of China Anti-Cancer Association. Guidelines and norms for diagnosis and treatment of breast cancer of China anti-cancer association (2021 Edition). China Oncol 2021; 31 (10) 954-1040
• 8 Chen QJ, Pei XH. Consensus on TCM syndrome differentiation and internal therapy for early-stage breast cancer. J Beijing Univ Tradit Chin Med Clin Med 2020; 27 (03) 5-8
• 9 Specialty Committee of Oncology of Chinese Association of the Integrative Medicine, Beijing Breast Disease Prevention and Treatment Society of Integrative Medicine Specialty Committee, National Expert Committee for the Integrative Prevention and Treatment of Breast Cancer of Beijing Integrative Chinese and Western Medicine Promotion Association for Prevention and Treatment of Chronic Diseases. Consensus on diagnosis and treatment of breast cancer with Integrative medicine. Chin J Front Med Sci 2021; 13 (07) 44-64
• 10 Lin HS. Guidelines of TCM Diagnosis and Treatment of Malignant Tumor. 2014 ed. Beijing: People's Medical Publishing House;; 2014
• 11 Zheng XY. Guidelines for the Clinical Research of Chinese Medicine New Herbs. Beijing:: China Medical Science Press;; 2002
• 12 Working Committee of Guidelines of the Chinese Clinical Oncology Association. Diagnosis and Treatment Guidelines of Breast Cancer of Chinese Society of Clinical Oncology-2019. Beijing:: People's Medical Publishing House;; 2019
• 13 Meng BX, Cheng XF, Jiang MQ. et al. Wang wanlin's experience in treating breast cancer with “tongfa”. Zhonghua Zhongyiyao Zazhi 2021; 36 (07) 4032-4036
• 14 Zeng YZ. Correlation between molecular classification of breast cancer and TCM staging syndrome differentiation. Nanjing:: Nanjing University of Chinese Medicine;; 2017
• 15 Zhang LX. Correlation between breast cancer-related gene expression and TCM syndrome and prognosis after breast cancer surgery. Guangzhou: Ji'nan University;; 2017